Introduction
============

Acute kidney injury (AKI) has an incidence of 30% in intensive care units (ICUs) \[[@B1]\] and most frequently occurs in multiple organ dysfunction syndrome (MODS) \[[@B2],[@B3]\]. Even though available studies do not demonstrate a reduction in mortality under continuous renal replacement therapy (CRRT) compared with intermittent hemodialysis \[[@B4],[@B5]\], CRRT has some advantages like slow and balanced fluid removal leading to minimal variability of plasma osmolality and electrolyte disturbances with better cardiovascular and hemodynamic tolerability \[[@B6]\]. The main disadvantage of CRRT is the requirement for anticoagulation to prevent clotting of the extracorporeal circuit, and severe bleeding has been reported in up to 30% of these patients, with heparin being the most commonly used anticoagulant \[[@B7],[@B8]\].

Regional citrate anticoagulation is an effective and safe alternative to heparin \[[@B7],[@B9]-[@B11]\]. Citrate is infused into the extracorporeal circuit and chelates ionized calcium, thereby inhibiting coagulation. Citrate and chelated calcium enter the dialysate and are removed from the hemocircuit with calcium chloride (CaCl~2~) infused systemically, replacing the losses of calcium. Citrate not dialyzed through the filters enters the systemic circulation of the patient and is metabolized to bicarbonate mainly by the liver. Non-metabolized citrate chelates ionized calcium, leading to a decrease in its concentrations \[[@B11]-[@B14]\]. CaCl~2~is continuously administered to achieve a steady state between citrate administration by central infusion and citrate elimination determined by liver metabolism. Once a steady-state citrate concentration is achieved, a normal ionized calcium concentration can be achieved by an increased total calcium concentration because a fraction of the ionized calcium is chelated by circulating systemic citrate. The total-to-ionized calcium ratio (T/I Ca^2+^ratio) should be directly proportional to the concentration of serum citrate \[[@B15],[@B16]\]. Therefore, impaired hepatic citrate metabolism leads to citrate accumulation and increases T/I Ca^2+^ratio with normal ionized calcium \[[@B13]\]. Thus, citrate accumulation is indicated indirectly by an elevated T/I Ca^2+^ratio. Patients with hepatic or multi-organ dysfunction (or both) can develop citrate accumulation characterized by low ionized calcium, elevated total calcium, and metabolic acidosis \[[@B12],[@B13]\]. In critically ill patients undergoing CRRT with regional citrate anticoagulation (CRRT-citrate), an increased T/I Ca^2+^ratio in about 33% of patients with severe hepatic impairment was found \[[@B13]\]. We prospectively evaluated the incidence and prognostic relevance of an increased T/I Ca^2+^ratio and its association to hepatic and multi-organ dysfunction in all patients undergoing CRRT-citrate in a medical ICU within a 2-year period.

Materials and methods
=====================

Patients
--------

With approval of the institutional review board (Ethical Committee of the Saarland, Germany, 211/11), we evaluated all critically ill patients with AKI and necessity for CRRT in the medical ICU of the University Hospital of Saarland from September 2009 to September 2011. Informed consent was obtained from all enrolled patients or substitute decision makers. Critical illness was defined by a commonly used score in intensive care medicine (Simplified Acute Physiology Score II, or SAPS II) \[[@B17]\]. Thus, critical illness and MODS were defined as a minimum SAPS II of 30 points. As shown in Figure [1](#F1){ref-type="fig"}, in our center, all patients with AKI and necessity for CRRT were assigned to regional citrate anticoagulation (CRRT-citrate). A steady state of calcium homeostasis was defined when a stable T/I Ca^2+^ratio after at least 36 hours of CRRT was achieved and when no changes in the infusion rates of CaCl~2~or citrate were necessary in the previous 36 hours. The primary endpoint was 28-day mortality. Secondary endpoints were changes in liver function and calcium homeostasis during citrate anticoagulation.

![**Study flowchart for all critically ill patients admitted to the intensive care unit within a two-year period**. All patients with acute kidney injury and necessity for continuous renal replacement therapy received regional citrate anticoagulation. Twenty-three patients were excluded from analysis because hemodynamic stabilization could not be achieved within 36 hours. After hemodynamic stabilization, 208 patients were analyzed for the study.](cc11363-1){#F1}

According to the American College of Chest Physicians evidence-based clinical practice guidelines \[[@B18],[@B19]\], in all patients on CRRT-citrate, unfractioned heparin (UFH) was given as an adjunctive in a thromboembolic prophylactic dose regimen (300 to 500 IU/hour intravenously). In cases of the demand for systemic effective anticoagulation (for example, deep venous thrombosis, pulmonary embolism, atrial fibrillation, mechanical heart valves, and decompensated heart failure), UFH was given in a therapeutic dosage. During the study period, in 11 patients (1.5%), a heparin-induced thrombocytopenia was diagnosed. These patients on CRRT-citrate were additionally treated with argatroban in therapeutic doses.

Safety
------

Patients underwent physical examination, hemodynamic measurements (blood pressure and heart rate), and clinical laboratory tests daily. Bleeding episodes were classified according to the modified McMaster criteria \[[@B20]\]. The episodes were defined as minor when bleeding signs occurred but no transfusion was needed and as major when transfusion of blood or coagulation factors became necessary.

Continuous renal replacement therapy protocol
---------------------------------------------

Vascular access for CRRT was established through a double-lumen central venous catheter. Continuous venovenous hemodialysis was performed with a polysulfone high-flux hemodialyzer by using a Fresenius multifiltrate (Fresenius, Bad Homburg, Germany) with a bicarbonate dialysate at a flow rate of 2,000 mL/hour. The blood flow was 100 mL/minute. The ultrafiltration rate depended on clinical requirements (0 to 200 mL/hour). The hemodialysis tubes and filters were renewed every 72 hours. We used regional anticoagulation with 4% trisodium citrate solution (Fresenius), which was administered in the extracorporeal circuit before the site of the hemofilter. We started with a standard dose of 4 mmol/L citrate/blood. In most patients, only minor corrections in this dosing were necessary (3.5 to 4.2 mmol/L) to achieve calcium levels of 0.25 to 0.35 mmol/L in the blood of the extracorporeal circuit. On average, 4 mmol/L citrate/blood flow was used. The postfilter CaCl~2~replacement was accomplished by CaCl~2~infusion given via a central line before reinfusion of blood into the patient. Citrate and CaCl~2~infusions were adjusted by the nursing team in accordance with the protocol of the manufacturer (Fresenius). The target level of intracorporeal ionized systemic calcium was between 0.9 and 1.2 mmol/L.

In cases (n = 16) of an increasing T/I Ca^2+^ratio of at least 2.4, which is an indirect sign of citrate accumulation, the dialysate flow was elevated up to 3,000 mL/hour in order to increase the citrate clearance. In two of these cases, as increasing dialysate flow was not efficient enough to reduce the ratio, blood flow was reduced to 80 mL/hour in order to reduce citrate offer for anticoagulation.

Laboratory tests
----------------

Ionized postfilter extracorporeal calcium and ionized systemic calcium were measured initially every 20 minutes until a steady state was achieved and then every 4 hours. Sodium, potassium, and arterial blood gases were analyzed every 4 hours. Hemoglobin, hematocrit, red and white blood cells, platelets, creatinine, urea, total calcium, chloride, total bilirubin, albumin, cholinesterase, prothrombin time, antithrombin III, and transaminases were measured daily.

Assessment of hepatic function
------------------------------

Transaminases, total bilirubin, albumin, cholinesterase, prothrombin time, and antithrombin III were measured daily. In patients with signs of progressive hepatic impairment and threatening hepatic failure, liver function was evaluated to avoid overdosage of administered therapeutics. For dynamic liver function, indocyanine green (ICG-PULSION; Pulsion Medical Systems, Munich, Germany) was injected in the central venous catheter (0.5 mg/kg). ICG is nearly exclusively eliminated by the liver unconjugatedly into the bile and does not undergo enterohepatic recirculation. Its elimination may be expressed as the plasma disappearance rate (ICG-PDR) and can be measured non-invasively at the bedside by transcutaneous pulse densitometry with a finger clip (LiMON monitoring; Pulsion Medical Systems). Normal values for ICG-PDR are considered to be more than 18% per minute. In general, ICG removal from the blood depends on liver blood flow, parenchymal cellular function, and biliary excretion \[[@B21]-[@B23]\]. ICG-PDR measurements were made once daily.

Statistical analysis
--------------------

Data are expressed as mean value ± standard error of the mean unless otherwise stated. All quantitative parameters were normally distributed (Kolmogorov-Smirnov test). Correlations of biomarkers were done by Pearson correlation coefficient. For quantitative data, we used one-way analysis of variance to compare three groups (T/I Ca^2+^ratio of less than 2.00, 2.00 to 2.39, and 2.40 or more) with Bonferroni *post hoc*test. Dependencies in contingency tables (categorical data) were analyzed with chi-squared test. Some biomarkers were used as diagnostic tests. The cutoff points were determined by the receiver operating characteristic (ROC) analysis. Survival curves were created by using the Kaplan-Meier method. Cox proportional hazards regression analysis was performed to determine predictor variables for 28-day survival. All statistical analyses were performed with StatView (SAS Institute Inc., Cary, NC, USA).

Results
=======

Baseline characteristics
------------------------

This prospective monocentric clinical study was performed at an interdisciplinary medical ICU. During a study period of 2 years, AKI was diagnosed in 233 of 923 critically ill patients (25.24%). In all 233 cases, CRRT-citrate was performed. A steady state of calcium homeostasis was defined when no changes in the infusion rates of CaCl~2~or citrate were necessary within 36 hours. Consecutively, 208 patients (89.3%) were analyzed (Figure [1](#F1){ref-type="fig"}) and were distributed into three groups by tertiles of T/I Ca^2+^ratio (less than 2.00, 2.00 to 2.39, and 2.40 or more). The main demographic data are presented in Table [1](#T1){ref-type="table"}. Among these three groups, there were no differences in age, gender, reasons for MODS and AKI, any history of kidney disease, and severity of critical illness as measured by SAPS II. In the highest calcium ratio tertile, patients with a history of liver disease were significantly cumulated (7.7% versus 6.7% versus 24.5%, *P*= 0.003). Laboratory parameters at the start, day 3, and last day of CRRT are depicted in Table [2](#T2){ref-type="table"}.

###### 

Baseline characteristics and concomitant therapies at start of continuous renal replacement therapy with regional citrate antigoagulation

  Characteristic or therapy                                    Ratio of total to ionized Ca^2+^   ANOVA                       
  ------------------------------------------------------------ ---------------------------------- ------------- ------------- ---------
  Number                                                       65                                 90            53            \-
  Age, years                                                   62.6 ± 1.9                         66.6 ± 1.5    62.8 ± 1.8    0.159
  Females/males, number                                        25/40                              38/52         27/26         0.382
  Reasons for critical illness and MODS, number (percentage)                                                                  
   Hemorrhagic shock                                           4 (6.2)                            3 (3.3)       2 (3.8)       0.778
   Septic-toxic shock                                          42 (61.6)                          64 (71.1)     38 (71.7)     0.951
   Cardiogenic shock                                           19 (29.2)                          23 (25.6)     13 (24.5)     0.396
  History of liver disease, number (percentage)                                                                               
   Child B-C liver cirrhosis                                   5 (7.7)                            6 (6.7)       13 (24.5)     0.003
  History of kidney disease, number                                                                                           
   K/DOQI 0-I                                                  51                                 67            47            0.331
   K/DOQI II                                                   2                                  8             1             0.123
   K/DOQI III                                                  2                                  2             0             0.463
   K/DOQI IV                                                   2                                  5             1             0.505
   K/DOQI V                                                    8                                  8             4             0.651
  Critical illness score, hemodynamics                                                                                        
   SAPS II, points                                             46 ± 1.2                           47 ± 1.1      49 ± 1.3      0.234
   Heart rate, beats per minute                                89 ± 2.4                           90 ± 1.8      98 ± 2.7      0.021
   Mean arterial pressure, mm Hg                               76.3 ± 1.8                         71.8 ± 1.2    68.6 ± 1.3    0.002
  Concomitant therapy                                                                                                         
  Mechanical ventilation, number (percentage)                  44 (67.69)                         64 (71.11)    40 (75.47)    0.650
   Vasopressors, number (percentage)                           44 (67.69)                         64 (71.11)    40 (75.47)    0.650
   Norepinephrine dose, µg/kg per minute                       0.08 ± 0.05                        0.10 ± 0.04   0.12 ± 0.04   \<0.001
   Dialysis function                                                                                                          
  Citrate, mmol/L                                              3.9 ± 0.1                          3.9 ± 0.1     3.8 ± 0.2     0.758
   Blood flow, mL/minute                                       100                                100           100           \-
   Dialysate flow, mL/hour                                     2,000                              2,000         2,000         \-
   Dialysis dose, mL/kg per hour                               25 ± 0.2                           26 ± 0.2      25 ± 0.2      0.483
   Filter patency, hours                                       67 ± 0.7                           69 ± 0.6      67 ± 0.8      0.136
   CRRT duration, days                                         19.7 ± 3.4                         11.4 ± 1.4    8.6 ± 0.9     0.002
  Reasons for CRRT termination, number (percentage)                                                                           
   Restoration of renal function                               62 (95.4)                          55 (61.1)     0 (0)         \<0.001
   Death of patient                                            3 (4.6)                            35 (38.9)     53 (100)      \<0.001
  Mortality, number (percentage)                                                                                              
   28-day mortality                                            3 (4.6)                            35 (38.9)     53 (100)      \<0.001
   Hospital mortality                                          18 (27.7)                          41 (45. 6)    53 (100)      \<0.001

Data are presented as number (percentage) or as mean ± standard error of the mean. Quantitative data were analyzed by analysis of variance (ANOVA). Categorical data were analyzed by chi-squared test. CRRT, continuous renal replacement therapy; K/DOQI, Kidney Disease Outcomes Quality Initiative; MODS, multiple organ dysfunction syndrome; SAPS II, Simplified Acute Physiology Score II.

###### 

Laboratory parameters at start, day 3, and last day of continuous renal replacement therapy

  Parameters                                 T/I-Ca^2+^ratio   Bonferroni *post hoc*test                                                                                                                                        
  ------------------------------------------ ----------------- --------------------------- -------------- --------------- -------------- -------------- --------------- -------------- -------------- --------------- --------- ---------
  **Critical illness score, hemodynamics**                                                                                                                                                            ***P*values**             
                                                                                                                                                                                                                                
   SAPS II, points                           46 ± 1.21         35 ± 1.45                   33 ± 1.07      47 ± 1.18       44 ± 1.38      42 ± 1.63      49 ± 1.27       59 ± 1.38      60 ± 1.41      \<0.001         \<0.001   \<0.001
   Heart rate, beats per minute              89 ± 2.37         88 ± 2.36                   77 ± 2.33      90 ± 1.79       89 ± 1.82      81 ± 2.42      98 ± 2.66       97 ± 2.65      104 ± 3.07     0.324           \<0.001   \<0.001
   MAP, mm Hg                                76.34 ± 1.83      76.34 ± 1.38                79.88 ± 1.69   71.82 ± 1.15    71.71 ± 1.15   73.16 ± 1.19   68.60 ± 1.29    68.61 ± 1.30   67.28 ± 1.50   \<0.001         \<0.001   \<0.001
   Liver function                                                                                                                                                                                                               
   Bilirubin, mg/dL                          2.21 ± 0.66       2.28 ± 0.66                 3.09 ± 0.81    2.63 ± 0.57     2.60 ± 0.58    2.99 ± 0.50    5.74 ± 1.30     6.09 ± 1.22    7.09 ± 1.25    0.799           \<0.001   \<0.001
   Albumin, g/L                              26.42 ± 0.73      25.82 ± 0.66                26.12 ± 0.72   28.11 ± 0.71    28.02 ± 0.65   27.33 ± 0.61   28.11 ± 0.86    27.42 ± 0.82   25.19 ± 0.86   0.003           0.258     0.118
   CHE × 10^3^, U/L                          4.52 ± 0.23       4.52 ± 0.23                 4.44 ± 0.23    4.31 ± 0.20     4.29 ± 0.20    4,12 ± 0.19    3.93 ± 0.25     3.93 ± 0.25    3.85 ± 0.25    0.159           0.001     0.035
   Prothrombin time, percentage              63.12 ± 3.00      72.83 ± 2.86                72.25 ± 2.79   60.12 ± 2.42    60.60 ± 2.48   61.88 ± 2.66   50.23 ± 3.12    52.59 ± 3.15   49.15 ± 3.27   \<0.001         \<0.001   \<0.001
   AT III, percentage                        69.71 ± 2.18      69.70 ± 2.17                70.37 ± 2.19   68.90 ± 2.21    68.84 ± 2.21   69.09 ± 2.25   58.45 ± 3.09    58.45 ± 3.09   57.59 ± 3.11   0.471           \<0.001   \<0.001
   ASAT, U/L                                 449 ± 144         298 ± 108                   186 ± 95       296 ± 78        404 ± 97       520 ± 126      817 ± 304       763 ± 209      1,237 ± 379    0.360           \<0.001   \<0.001
   ALAT, U/L                                 204 ± 74          163 ± 59                    119 ± 56       180 ± 48        239 ± 52       251 ± 53       431 ± 174       446 ± 121      462 ± 115      0.544           0.072     \<0.001
   γ-GT, U/L                                 133 ± 18          125 ± 17                    222 ± 34       144 ± 18        133 ± 15       199 ± 30       121 ± 20        129 ± 20       127 ± 19       0.519           0.072     0.188
   ICG-PDR, percentage/minute                15.02 ± 0.61      18.78 ± 0.43                19.60 ± 0.58   13.93 ± 0.47    15.26 ± 0.55   16.04 ± 0.65   11.16 ± 0.64    9.26 ± 0.56    8.83 ± 0.55    \<0.001         \<0.001   \<0.001
  Dialysis function, mg/dL                                                                                                                                                                                                      
   Urea                                      123.03 ± 8.31     63.71 ± 5.13                53.79 ± 5.01   115.48 ± 7.78   58.97 ± 3.62   47.49 ± 3.24   121.38 ± 9.22   63.83 ± 5.00   54.55 ± 5.15   0.295           0.995     0.324
   Blood urea nitrogen                       57.46 ± 3.88      29.75 ± 2.39                25.12 ± 2.34   53.93 3.64      27.54 ± 1.69   22.18 ± 1.51   56.48 ± 4.77    29.81 ± 2.34   25.48 ± 2.41   0.295           0.995     0.324
   Creatinine                                4.14 ± 0.29       2.14 ± 0.16                 1.77 ± 0.16    3.14 ± 0.20     1.75 ± 0.10    1.59 ± 0.10    3.07 ± 0.28     1.88 ± 0.11    1.65 ± 0.11    0.002           0.009     0.867
  Ca homeostasis and chloride                                                                                                                                                                                                   
   Ca^2+^extracorporeal, mmol/L              0.29 ± 0.01       0.29 ± 0.01                 0.29 ± 0.01    0.29 ± 0.01     0.30 ± 0.01    0.30 ± 0.01    0.29 ± 0.01     0.30 ± 0.01    0.30 ± 0.01    0.586           0.096     0.189
   Total Ca^2+^, mmol/L                      1.97 ± 0.03       2.07 ± 0.03                 2.10 ± 0.03    2.14 ± 0.02     2.29 ± 0.03    2.25 ± 0.03    2.30 ± 0.03     2.49 ± 0.03    2.42 ± 0.05    \<0.001         \<0.001   \<0.001
   Ionized Ca^2+^, mmol/L                    1.04 ± 0.02       1.11 ± 0.01                 1.11 ± 0.01    1.04 ± 0.01     1.06 ± 0.02    1.05 ± 0.01    0.98 ± 0.02     0.99 ± 0.01    0.98 ± 0.02    \<0.001         \<0.001   \<0.001
   T/I-Ca^2+^ratio                           1.90 ± 0.02       1.87 ± 0.01                 1.89 ± 0.02    2.07 ± 0.02     2.16 ± 0.01    2.15 ± 0.02    2.36 ± 0.04     2.53 ± 0.02    2.49 ± 0.04    \<0.001         \<0.001   \<0.001
   Chloride, mmol/L                          108 ± 0.45        107 ± 0.58                  107 ± 0.62     108 ± 0.51      108 ± 0.78     107 ± 0.54     108 ± 0,36      107 ± 0.55     108 ± 0.34     0.587           0.781     0.672
  Acid-base balance                                                                                                                                                                                                             
   pH                                        7.38 ± 0.01       7.43 ± 0.01                 7.43 ± 0.01    7.40 ± 0.01     7.43 ± 0.01    7.42 ± 0.01    7.37 ± 0.01     7.41 ± 0.01    7.39 ± 0.01    0.384           \<0.001   \<0.001
   pCO~2~, mm Hg                             38.77 ± 1.48      37.81 ± 0.78                38.09 ± 0.72   35.59 ± 0.69    37.61 ± 0.60   39.25 ± 0.69   35.81 ± 0.98    37.98 ± 0.86   38.59 ± 1.22   0.242           0.301     0.994
   HCO~3~, mm Hg                             22.77 ± 0.53      25.10 ± 0.36                25.61 ± 0.54   22.41 ± 0.38    24,34 ± 0.36   25.28 ± 0.46   20.68 ± 0.42    23.13 ± 0.54   23.40 ± 0.67   0.273           \<0.001   \<0.001
  Hematology                                                                                                                                                                                                                    
   Hemoglobin, g/dL                          10.29 ± 0.26      9.24 ± 0.22                 9.24 ± 0.22    10.30 ± 0.19    9.98 ± 0.27    9.98 ± 0.27    10.14 ± 0.28    9.56 ± 0.25    9.54 ± 0.25    0.009           0.495     0.081
   Platelets, 10^9^/L                        164 ± 10.67       147 ± 9.51                  152 ± 10.99    147 ± 8.96      135 ± 7.94     127 ± 8.22     122 ± 12.88     101 ± 12.18    77 ± 10.58     0.025           \<0.001   \<0.001

Data are presented as mean ± standard error of the mean. Quantitative data were analyzed by Bonferroni *post hoc*test. γ-GT, gamma-glutamylcyclotransferase; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; AT III, antithrombin III; CHE, cholinesterase; HCO~3~, bicarbonate; ICG-PDR, indocyanine green plasma disappearance rate; MAP, mean arterial pressure; pCO~2~, carbon dioxide partial pressure; SAPS II, Simplified Acute Physiology Score II; T/I-Ca^2+^ratio, total-to-ionized calcium ratio.

Outcomes
--------

Higher T/I Ca^2+^ratio was associated with a significant increase in 28-day mortality (4.6% versus 38.9% versus 100%, *P*\<0.001) (Table [1](#T1){ref-type="table"}). Cox regression analysis, including age, gender, heart rate, mean arterial blood pressure, bilirubin, albumin, cholinesterase acticity, prothrombin time index, ICG clearance, acid-base balance, and total and ionized calcium levels and their ratio, was performed. Only albumin (*P*\<0.001), ICG clearance (*P*\<0.001), and total and ionized calcium levels (*P*\<0.001) and their ratio (*P*\<0.004) were significant independent predictors for 28-day mortality. ROC analysis, calculating the area under the curve (AUC), showed a high accuracy in predicting mortality for the T/I Ca^2+^ratio (AUC of 0.938 ± 0.02, *P*\<0.001) at day 3. This accuracy was as high as the predictability of the well-established ICG clearance (AUC of 0.941 ± 0.02, *P*\<0.001) (Figure [2](#F2){ref-type="fig"}). In ROC analysis, a cutoff for the T/I Ca^2+^ratio of at least 2.4 had a prognostic sensitivity of 55.6% (95% confidence interval (CI) 44.7% to 66.0%) and a specificity of 99.2% (95% CI 95.4% to 99.9%) to determine 28-day mortality. In the Kaplan-Meier survival analysis, patients with a ratio of at least 2.4 had the highest mortality rates (Figure [3a](#F3){ref-type="fig"}: baseline; Figure [3b](#F3){ref-type="fig"}: levels on day 3). The log-rank tests for all of these survival curves were significantly different (*P*\<0.001). The hazard ratio for mortality was 33.5-fold higher for a T/I Ca^2+^ratio of at least 2.4 than for a ratio of less than 2.4 (Table [3](#T3){ref-type="table"}).

![**Receiver operating characteristic curves for T/I-Ca^2+^-ratio and ICG-PDR**. AUC: area under the curve, T/I Ca^2+^ratio: total-to-ionized calcium ratio, ICG-PDR: indocyanine green plasma disappearance rate.](cc11363-2){#F2}

![**Kaplan-Meier survival analysis using T/I Ca^2+^ratio at start (a) and on day 3 (b)**. A Log-rank test (p-value) was performed.](cc11363-3){#F3}

###### 

Hazard ratio for 28-day mortality

                                         Hazard ratio   95% confidence interval   *P*value
  -------------------------------------- -------------- ------------------------- ----------
  Total-to-ionized Ca^2+^ratio (day 3)                                            
   \<2 versus ≥2                         4.17           2.76-6.29                 \<0.001
   \<2.2 versus ≥2.2                     25.13          15.49-40.77               \<0.001
   \<2.4 versus ≥2.4                     33.50          18.18-61.71               \<0.001
  ICG-PDR (day 3)                                                                 
   \<16 versus ≥16                       10.93          7.09-16.84                \<0.001
   \<12 versus ≥12                       28.63          16.41-49.94               \<0.001
   \<8 versus ≥8                         26.09          12.44-54.72               \<0.001

ICG-PDR, indocyanine green plasma disappearance rate.

Total-to-ionized calcium ratio and hepatic or multi-organ dysfunction or both
-----------------------------------------------------------------------------

None of the patients on CRRT-citrate developed relevant signs of hypo- or hypercalcemia, chloride overload because of CaCl~2~infusion, or any signs of citrate toxicity. Mean pH values, carbon dioxide partial pressure (pCO~2~), and bicarbonate levels remained in a normal range during the whole study period (Table [2](#T2){ref-type="table"}). Nevertheless, according to the distribution of patients in the predefined T/I Ca^2+^ratio tertiles after achieving a steady state of calcium homeostasis after 72 hours, total calcium concentrations and T/I Ca^2+^ratios were already elevated at baseline in tertile 3 (*P*\<0.001) (Table [2](#T2){ref-type="table"}). Patients in tertile 3 were associated with a significantly decreased hepatic clearance, measured by the ICG-PDR. This contrasted to patients in tertiles 1 and 2 in whom hepatic clearance increased significantly (*P*\<0.001) (Table [2](#T2){ref-type="table"}). Strikingly, according to the duration of CRRT (baseline, day 3, and last day), T/I Ca^2+^ratios and ICG-PDR clearances had a strong inverse correlation (r^2^= 0.42, *P*\<0.001) (Figure [4a](#F4){ref-type="fig"}). From the static liver function parameters, bilirubin trended toward higher levels and prothrombin time index was significantly reduced (*P*\<0.001) in tertile 3, whereas albumin and cholinesterasis did not differ significantly between the tertiles. Thus, monitoring of liver enzymes and hepatic protein synthesis is not sensitive enough to detect functional metabolic hepatic impairment. Within the T/I Ca^2+^ratio tertiles, the severity of critical illness changed. Although SAPS II decreased in tertiles 1 and 2, we observed a time-dependent significant increase of SAPS II in tertile 3 (*P*\<0.001) (Table [2](#T2){ref-type="table"}). We found a significant correlation between the T/I Ca^2+^ratios and the SAPS II (r^2^= 0.42, *P*\<0.001) (Figure [4b](#F4){ref-type="fig"}).

![**Total-to-ionized calcium ratio (T/I Ca^2+^ratio) and hepatic or multi-organ dysfunction or both**. Correlation between the T/I Ca^2+^ratio and hepatic clearance measured by the indocyanine green plasma disappearance rate (ICG-PDR) **(a)**and multi-organ dysfunction measured by Simplified Acute Physiology Score II (SAPS II) **(b)**on day 3 of continuous renal replacement therapy with regional citrate antigoagulation. A Cox regression analysis was performed.](cc11363-4){#F4}

Dialysis therapy, efficacy, and safety
--------------------------------------

CRRT-citrate was performed with a blood flow of 100 mL/hour, a dialysate flow of 2,000 mL/hour, and a dialysis dose (adjusted by patient weight) of 25 ± 0.2 versus 26 ± 0.2 versus 25 ± 0.3 mL/kg per hour (*P*= 0.483) (Table [1](#T1){ref-type="table"}). In 16 of 53 patients (30.2%) with an elevated T/I Ca^2+^ratio of at least 2.4, dialysate flow was raised up to 3,000 mL/hour in order to increase the citrate clearance; if necessary, as a second step, blood flow was raised down to 80 mL/hour in order to reduce citrate offer for anticoagulation. These procedures were effective, avoiding a further increase of T/I Ca^2+^ratio and citrate accumulation. CRRT-citrate was effective for all patient groups, as evidenced by the average fall in urea, blood urea nitrogen, and creatinine (*P*\<0.001) (Table [2](#T2){ref-type="table"}). After achieving a steady state and comparing these parameters on the last day of therapy, they did not differ significantly. The hemodialysis tubes and filters were renewed every 67 ± 0.7 versus 69 ± 0.6 versus 67 ± 0.8 hours (*P*= 0.136) (Table [1](#T1){ref-type="table"}). Fifty-five filters (5.3%) were substituted because of technical problems and vascular access malfunction. No patient developed severe bleeding.

Discussion
==========

CRRT-citrate is effective and safe, particularly in critically ill patients with elevated bleeding risks \[[@B7],[@B9],[@B10],[@B24]\]. In cases of hepatic or multi-organ dysfunction or both, citrate metabolism can be impaired, resulting in citrate accumulation detected indirectly by an elevated T/I Ca^2+^ratio \[[@B9],[@B13]\]. So far, the incidence and prognostic relevance of an elevated T/I Ca^2+^ratio on CRRT-citrate patients remain unclear. We prospectively evaluated the prognostic relevance of the T/I Ca^2+^ratio in all critically ill patients with AKI undergoing CRRT-citrate in a medical ICU within a 2-year period. We demonstrate, for the first time, that the T/I Ca^2+^ratio (a) emerged as an independent predictor of 28-day mortality in critically ill patients on CRRT-citrate and was associated (b) with hepatic impairment and (c) with multi-organ dysfunction.

Monitoring the T/I Ca^2+^ratio in patients on CRRT-citrate is an easy procedure with high therapeutic and prognostic impact. As shown in our study, measuring of total and ionized calcium levels and calculating their ratio provided independent predictors for 28-day mortality in patients on CRRT-citrate. A T/I Ca^2+^ratio of at least 2.4 had a prognostic sensitivity of 55.6% and a specificity of 99.2% to determine 28-day mortality. In the Kaplan-Meier survival analysis, patients with a ratio of at least 2.4 had the highest mortality rates; in these patients, the risk to die was 33.5-fold higher than in patients with a ratio of less than 2.4. Larger studies may be required to define the cutoff point with the greatest diagnostic and prognostic efficiency more precisely.

It remains unclear whether changes in calcium homeostasis are only markers of critical illness and comorbidity or whether they independently contribute to mortality. First of all, ionized calcium levels remained within the normal range by continuous CaCl~2~infusion and are unlikely to influence patient outcomes. Furthermore, serum chloride levels were not changed. Only extreme abnormalities of ionized calcium were reported to be independent predictors of mortality \[[@B25],[@B26]\]. Second, total calcium levels were increased in cases of citrate accumulation caused by hepatic or multi-organ dysfunction or both. In acute stressor states, increased total calcium levels cause a shift of calcium from the circulating pool to intracellular compartments and facilitate an intracellular calcium overload \[[@B27]\], inducing oxidative stress, permeability, and apoptotic cell death \[[@B26]\]. Furthermore, calcium administration increased mortality in animal models of sepsis \[[@B28],[@B29]\].

Therefore, therapeutic strategies target the early detection of either elevated total calcium levels or elevated T/I Ca^2+^ratio caused by citrate accumulation in patients on CRRT-citrate. Citrate levels could be decreased by increasing citrate clearance through the use of a higher dialysate flow, by reducing the blood flow (resulting in a reduced need for citrate anticoagulation), or by reducing the citrate offer in the extracorporeal circuit. Under these strategies, the use of a higher dialysate flow (2,000 to 3,000 mL/hour) is associated with increased diffusion mechanisms and is very effective in citrate clearance \[[@B30]\]. Reducing blood flow by 20% (from 100 to 80 mL/hour) is associated with a decreased need of citrate for anticoagulation, but its effectiveness in lowering citrate levels is less compared with increasing dialysate flow \[[@B30]\]. Lowering citrate offer by reducing the citrate dose (3.5 to 4.2 mmoL/L) in the extracorporeal circuit is associated with an increased risk for coagulopathy and is recommended only in selected patients according to safety and filter patency criteria.

In critically ill patients on CRRT-citrate, total calcium levels and the T/I Ca^2+^ratio were increased in cases of citrate accumulation. This decreased citrate metabolism can be caused by a hepatic or multi-organ dysfunction or both. We found a surprisingly high incidence of an increased T/I Ca^2+^ratio: close to 25%. Meier-Kriesche and colleagues \[[@B13]\] described an incidence of 12%. Another retrospective cohort study found, in patients with hepatic impairment, lower ionized calcium levels without elevated T/I Ca^2+^ratio \[[@B9]\]. Neither study reported the severity of critical illness.

Monitoring liver enzymes and hepatic protein synthesis has only limited diagnostic sensitivity for hepatic dysfunction \[[@B31],[@B32]\]. The dynamic hepatic clearance test, the indocyanine green plasma disappearance rate (ICG-PDR), is a valuable tool for sensitive and specific assessment of liver function and is shown to correlate with outcomes in critically ill patients \[[@B21]-[@B23]\]. Our data demonstrate a significant inverse correlation between hepatic function measured by the ICG-PDR and the T/I Ca^2+^ratio in patients on CRRT-citrate. Although an increase in the T/I Ca^2+^ratio was observed, critical levels were not achieved. Thus, hepatic impairment does not represent a contraindication for the use of regional anticoagulation with citrate. Elevated T/I Ca^2+^ratios were also associated with the severity of critically illness, as measured by SAPS II. This could be caused by poor tissue perfusion because citrate metabolism takes place in tissues rich in mitochondria, such as liver, skeletal muscles, and kidney. Therefore, a very close monitoring of calcium homeostasis in patients with hepatic impairment and MODS is strongly recommended to detect early citrate accumulation.

Conclusions
===========

In patients on CRRT-citrate, T/I Ca^2+^ratio is closely related to the clinical outcome and emerged as an independent predictor of 28-day mortality. Larger studies are required to define the cutoff and predictive value for the T/I Ca^2+^ratio. This ratio is associated with hepatic or multi-organ dysfunction or both and therefore is an important therapeutic target.

Key messages
============

In critically ill patients on CRRT-citrate, an elevated T/I Ca^2+^ratio

• is an independent predictor for 28-day mortality,

• is associated with hepatic or multi-organ dysfunction or both,

• is an indirect marker of systemic citrate accumulation, and

• signals the necessity to increase citrate clearance.

Abbreviations
=============

AKI: acute kidney injury; AUC: area under the curve; CaCl~2~: calcium chloride; CI: confidence interval; CRRT: continuous renal replacement therapy; CRRT-citrate: continuous renal replacement therapy with regional citrate antigoagulation; ICG: indocyanine green; ICG-PDR: indocyanine green plasma disappearance rate; ICU: intensive care unit; MODS: multiple organ dysfunction syndrome; ROC: receiver operating characteristic; SAPS II: Simplified Acute Physiology Score II; T/I Ca^2+^ratio: total-to-ionized calcium ratio; UFH: unfractioned heparin.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

AL helped to initiate the study, to perform CRRT, and to conduct all the investigations and the statistical analysis of the data and drafted the manuscript. MK helped to initiate the study and to administer CRRT. AL-G and DF helped to administer CRRT. TS was responsible for data management. RR, JP, and MB helped to conduct all the investigations and the statistical analysis of the data. All authors participated in interpreting the data and read and approved the final manuscript.

Acknowledgements
================

We are indebted to all patients involved in the study.
